Abstract
Given the high prevalence of emotional disorders within patients withcancer, identifying these comorbidities is essential in providing patientcentric care within a multidisciplinary team environment. The Depression Anxiety Stress Scale Short Form (DASS)‐21 is an empirically developed self‐report measure which assesses anxiety, depression and stress. The conceptual basis of DASS is a tripartite model1comprising 3 subscales: anxiety (DASS‐A—autonomic arousal,physiological hyperarousal, and situational anxiety), depression(DASS‐D—anhedonia, hopelessness, and dysphoria) and stress (DASS‐S—nondiscriminating anxiety and depression items that pre-dominantly consisted of tension, nervous arousal, and irritability) andprovides a global measure of psychological distress.
Because of the positive psychometric properties and ease of use,1the DASS‐21 is increasingly used in a cross section of oncology set-tings to assess psychological distress but has not been validated inthe cancer population. Our study aimed to examine the assumptions of the structure ofthe DASS‐21 within a cancer population actively receiving chemother-apy treatment in an outpatient setting and evaluate its psychometric properties.
Because of the positive psychometric properties and ease of use,1the DASS‐21 is increasingly used in a cross section of oncology set-tings to assess psychological distress but has not been validated inthe cancer population. Our study aimed to examine the assumptions of the structure ofthe DASS‐21 within a cancer population actively receiving chemother-apy treatment in an outpatient setting and evaluate its psychometric properties.
Original language | English |
---|---|
Pages (from-to) | 695-699 |
Number of pages | 5 |
Journal | Psycho-Oncology |
Volume | 27 |
Issue number | 2 |
Early online date | 18 Apr 2017 |
DOIs | |
Publication status | Published - Feb 2018 |